What is the place of pre-exposure prophylaxis in HIV prevention?

AIDS Reviews

Volumn 15, Issue 2, 2013, Pages 102-111

  De Man, Jeroen ^a   Colebunders, Robert ^a   Florence, Eric ^a   Laga, Marie ^a   Kenyon, Christopher ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Cost effectiveness; HIV prevention; Pre exposure prophylaxis; Program implementation; Risk compensation

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTEGRASE INHIBITOR; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BONE DENSITY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; GASTROINTESTINAL SYMPTOM; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; INCIDENCE; KIDNEY DISEASE; MEN WHO HAVE SEX WITH MEN; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PROPHYLAXIS; PROSTITUTION; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; UNPROTECTED SEX; VAGINA RING; VOMITING; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; PROGRAM DEVELOPMENT; RISK FACTOR;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK FACTORS;

EID: 84883159514     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. UNAIDS. Progress Report 2011. Available from: http://www.unaids.org/en/ media/unaids/contentassets/documents/unaidspublication/2011/20111130-ua-report- en.pdf
2. WHO. GLOBAL HIV/AIDS RESPONSE, Epidemic update and health sector progress towards Universal Access. Progress Report 2011.
3. Hankins C, De Zalduondo B. Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010;24(Suppl 4):S70-80.
4. Velasco-Hernandez J, Gershengorn H, Blower S. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis. 2002;2:487-93.
5. Cohen M, Chen Y, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
6. Siegfried N, Van der Merwe L, Brocklehurst P, Sint T. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011:CD003510.
7. Okwundu C, Uthman O, Okoromah C. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012:CD007189.
8. Young T, Arens F, Kennedy G, Laurie J, Rutherford G. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007:CD002835.
9. Gallant J, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Diseases. 2003;37:944-50.
10. Derdelinckx I, Wainberg M, Lange J, Hill A, Halima Y, Boucher C. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med. 2006;3:e454.
11. Nelson M, Katlama C, Montaner J, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-81.
12. U.S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm
13. U.S. Center for Disease Control (CDC). Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. 2011. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm
14. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR. 2011;60:65-8.
15. García-Lerma J, Heneine W. Animal models of antiretroviral prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2012;7:505-13.
16. Grant R, Lama J, Anderson P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
17. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N EnglJ Med. 2012;367:399-410.
18. Thigpen M, Kebaabetswe PM, Paxton L, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-34.
19. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). 20th CROI, Atlanta, Georgia. 2013. [Abstract].
20. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-22.
21. Patterson K, Prince H, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Translat Med. 2011;3:112re4.
22. Celum C, Baeten J. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis. 2012;25:51-7.
23. Abdool Karim Q, Abdool Karim S, Frohlich J, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-74.
24. U.S. National Institutes of Health (NIH). Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1). 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01386294?te rm=FACTS+001%26rank=1
25. NIH. Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services. 2013. Available from: http://clinicaltrials. gov/ct2/show/NCT01691768?term=caprisa+008&rank=1
26. Tangmunkongvorakul A, Chariyalertsak S, Amico K, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2012 [Epub ahead of print].
27. Van Griensven F, Thienkrua W, Sukwicha W, et al. Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. J Int AIDS Soc. 2010;13:13.
28. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PloS One. 2012;7:e33103.
29. NIH. The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP). 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01327651?term=intermittent+PrEP& rank=4
30. NIH. On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men. 2013. Available from: http://clinicaltrials.gov/ ct2/show/NCT01473472?term=ipergay&rank=1
31. Padian N, McCoy S, Karim S, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378:269-78.
32. Kiser P, Johnson T, Clark J. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012;14:62-77.
33. NIH. Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women. 2013. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT01539226
34. NIH. Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women. 2013. Available from: http://www. clinicaltrials.gov/ct2/show/NCT01617096?term=dapivirine+phase+3&rank=1
35. NIH. In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01813162?term=tdf+vaginal+ring&rank=1
36. NIH. Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA. 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01275443
37. Andrews C, Gettie A, Russell-Lodrigue K, et al. Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV. 20th CROI, Atlanta, Georgia. 2013. [Abstract].
38. Amico K, Mansoor L, Corneli A, Torjesen K, Van der Straten A. Adherence support approaches in biomedical HIV prevention trials: Experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013. [Epub ahead of print].
39. Haberer J, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14:1340-6.
40. Fung H, Stone E, Piacenti F. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002;24:1515-48.
41. Gilead Sciences. Investigator's Brochure: tenofovir disoproxil fumarate. 2004.
42. Gilead Sciences. Investigator's Brochure: emtricitabine/tenofovir disoproxil fumarate tablets. 2005.
43. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2:e27.
44. Cotter A, Powderly W. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501-15.
45. Gallant J, Winston J, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155-63.
46. Mayer K, Maslankowski L, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543-51.
47. Supervie V, García-Lerma J, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Nat Acad Sci USA. 2010;107:12381-6.
48. Paltiel A, Freedberg K, Scott C, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806-15.
49. Desai K, Sansom S, Ackers M, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829-39.
50. Juusola J, Brandeau M, Owens D, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-50.
51. Pretorius C, Stover J, Bollinger L, Bacaër N, Williams B. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PloS One. 2010;5:e13646.
52. Hallett T, Baeten J, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8:e1001123.
53. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett T. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27:447-58.
54. Gomez G, Borquez A, Caceres C, et al. The potential impact of preexposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med. 2012;9:e1001323.
55. Schackman B, Eggman A. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS. 2012;7:587-92.
56. Walensky R, Park J-E, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54:1504-13.
57. Williams B, Abdool Karim S, Karim Q, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immun Defic Syndr. 2011;58:207-10.
58. Cassell M, Halperin D, Shelton J, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ. 2006;332:605-7.
59. Karlaftis M, Kotzampassakis I, Kanellaidis G. An empirical investigation of European drivers' self-assessment. J Saf Res. 2003;34:207-13.
60. Adams J. Risk. Routledge; 1995. p. 228.
61. Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. Lancet. 2000;355:400-3.
62. Wilde G. Target Risk: Dealing with the danger of death, disease and damage in everyday decisions. PDE publications Toronto; 1994.
63. Allen T, Heald S. HIV/AIDS policy in Africa: what has worked in Uganda and what has failed in Botswana? J Intern Develop. 2004;16:1141-54.
64. Ostrow D, Fox K, Chmiel J, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 2002;16:775-80.
65. Van de Ven P, Kippax S, Knox S, Prestage G, Crawford J. HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS. 1999;13:2289-94.
66. Stolte I, Dukers N, Geskus R, Coutinho R, De Wit J. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS. 2004;18:303-9.
67. Stolte G, Dukers N, De Wit J, Fennema H, Coutinho R. A summary report from Amsterdam: increase in sexually transmitted diseases and risky sexual behaviour among homosexual men in relation to the introduction of new anti-HIV drugs. Eur Commun Dis Bull. 2002;7:19-22.
68. Elford J, Bolding G, Maguire M, Sherr L. Combination therapies for HIV and sexual risk behavior among gay men. J Acquir Immun Defic Syndr. 2000;23:266-71.
69. Crepaz N, Hart T, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004; 292:224-36.
70. CDC. PrEP: A New Tool for HIV Prevention (CDC factsheet). 2012. Available from: http://www.cdc.gov/hiv/prep/pdf/PrEPfactsheet.pdf
71. Grant R, Guanira J, Buchbinder S, et al. No excess in HIV incidence after stopping oral emtricitabine/tenofovir pre-exposure prophylaxis: The iPrEx Trial. Presented at the 20th CROI, Atlanta, Georgia, 2013. [Abstract].
72. Morris M, Epstein H, Wawer M. Timing is everything: international variations in historical sexual partnership concurrency and HIV prevalence. PloS One. 2010;5:e14092.
73. Morris M, Epstein H. Role of concurrency in generalised HIV epidemics. Lancet. 2011;378:1843-4.
74. Shelton J. Role of concurrency in generalised HIV epidemics. Lancet. 2011;378:1843-4.
75. Green E. Rethinking AIDS Prevention: Learning from Successes in Developing Countries. Greenwood Publishing Group; 2003 p. 374.
76. Kirby D. Changes in sexual behaviour leading to the decline in the prevalence of HIV in Uganda: confirmation from multiple sources of evidence. Sex Transm Infect. 2008;84(Suppl 2):ii35-41.
77. Stoneburner R, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science. 2004;304:714-18.
78. Shisana O. The Impact of HIV/Aids on the Health Sector: National Survey of Health Personnel, Ambulatory and Hospitalised Patients, and Health Facilities 2002. HSRC Press; 2003. p. 175.
79. Shisana O. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008: A Turning Tide Among Teenagers?. Human Sciences Research Council; 2009. p. 98.
80. Halldorsdottir I. Evaluation of a behaviour change communication programme to reduce concurrent sexual partnerships in Botswana. 19th International AIDS Conference; Washington DC. 2012. [Abstract].
81. Shisana O. South African National HIV Prevalence, HIV Incidence, Behaviour and Communication Survey, 2005. HSRC Press; 2005. p. 156.
82. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural Kwa- Zulu-Natal, South Africa. Science. 2013;339:966-71.
83. UNAIDS. Botswana Country Profile. 2013. Available from: http://www.unaids.org/en/regionscountries/countries/botswana/
84. Weller S. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Social Sci Med. 1993;36:1635-44.
85. Epstein H, Morris M. Concurrent partnerships and HIV: an inconvenient truth. J Int AIDS Soc. 2011;14:13.
86. CDC. 2010 STD Treatment Guidelines for sexually transmitted diseases. Available from: http://www.cdc.gov/std/treatment/2010/default.htm
87. Rucinski K, Mensah N, Sepkowitz K, Cutler B, Sweeney M, Myers J. Knowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York City. AIDS Behav. 2013 [Epub ahead of print].
88. About Microbicides. Microbicide Trials Network. 2013. Available from: http://www.mtnstopshiv.org/node/706
89. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-404.
90. Donnell D, Baeten J, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-8.